The pulmonary arterial hypertension quality enhancement research initiative: Comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH

Annals of the Rheumatic Diseases

Volumn 71, Issue 2, 2012, Pages 249-252

  Clements, Philip J ^a   Tan, Mary ^b   McLaughlin, Vallerie V ^c   Oudiz, Ronald J ^d   Tapson, Victor F ^e   Channick, Richard N ^f   Rubin, Lewis J ^g   Langer, Anatoly ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CANADIAN HEART RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL RESEARCH; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC TEST; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; HUMAN; IDIOPATHIC PULMONARY HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SPIROMETRY; SURVIVAL RATE; SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEX FACTORS; TREATMENT OUTCOME;

EID: 84855358253     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200265     Document Type: Article

References (18)

1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.
2. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28. (Pubitemid 46981654)
3. Hachulla E, Denton CP. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management. Eur Respir Rev 2010;19:314-20.
4. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):14S-34S. (Pubitemid 38932340)
5. Chang B, Schachna L, White B, et al. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006;33:269-74. (Pubitemid 43209302)
6. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23. (Pubitemid 17137857)
7. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
8. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S78-84.
9. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-10. (Pubitemid 351194756)
10. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164- 72.
11. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63.
12. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010;138:1383-94.
13. McLaughlin VV, Langer A, Dragomir A, et al. Contemporary trends in the diagnosis and management of PAH: an initiative to close the care gap. Chest 2010;138:351A.
14. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003;123:344-50. (Pubitemid 36269414)
15. Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
16. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009;179:151-7.
17. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S55-66.
18. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.